Background and Purpose-Previous experimental studies suggested that serum netrin-1 was associated with the progression of ischemic stroke. Knowledge about netrin-1 among ischemic stroke patients may provide new ideas for the prognostic assessment of ischemic stroke. The aim of this study was to investigate the association between serum netrin-1 and prognosis of ischemic stroke. Methods-Serum netrin-1 levels at baseline were measured for 3346 ischemic stroke patients from the CATIS (China Antihypertensive Trial in Acute Ischemic Stroke), and all patients were followed up at 3 months after stroke onset. The primary outcome was a combination of death and major disability (modified Rankin Scale score of ≥3) within 3 months after stroke onset. Results-Up to 3 months after stroke onset, 845 patients (25.25%) experienced death or major disability. After adjustment for baseline National Institutes of Health Stroke Scale score and other potential confounders, elevated serum netrin-1 was associated with a decreased risk of primary outcome (odds ratio, 0.65; 95% CI, 0.47-0.88; P trend =0.002) when 2 extreme quartiles were compared. Each SD increase of log-transformed netrin-1 was associated with 17% (95% CI, 7%-26%) decreased risk of primary outcome. Multivariable-adjusted spline regression models showed a negative linear dose-response relationship between serum netrin-1 and the risk of primary outcome (P linearity =0.003). Adding netrin-1 quartile to a model containing conventional risk factors improved risk prediction for primary outcome (net reclassification improvement index =14.74%; P=0.002; integrated discrimination improvement =0.40%; P=0.005). Conclusions-Elevated serum netrin-1 levels were associated with improved prognosis at 3 months after ischemic stroke, suggesting that serum netrin-1 may be a potential prognostic biomarker for ischemic stroke. Further studies from other samples of ischemic stroke patients are needed to replicate our findings and to clarify the potential mechanisms. Clinical Trial Registration-URL: https://www.clinicaltrials.gov. Unique identifier: NCT01840072. (Stroke. 2019;50:845-852.
S
troke is the second most common cause of death and the leading cause of long-term disability worldwide, 1 and ischemic stroke is the most common kind of stroke. 2 It is reported that ischemia, reperfusion injury, and apoptosis are involved in the pathogenesis of neurological damage after ischemic stroke. 3 Netrin-1 is a laminin-related protein which regulates axon guidance and angiogenesis. 4 It has been reported that netrin-1 has anti-inflammatory properties, 5, 6 and it can inhibit the apoptosis of endothelial cell and neuron cell. 7, 8 Data from experimental studies demonstrated that netrin-1 could rescue neuron loss and reduce infarct volume through attenuating apoptosis and promoting migration of neuron. 9 In addition, overexpression of netrin-1 was found to be able to improve poststroke neurovascular structure and functional recovery in ischemic stroke rats. 10 Recently, several studies also discovered that
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netrin-1 could also promote neuronal regeneration in ischemic regions, 7 reduce ischemia-reperfusion injury 11 and regulate blood-brain barrier maintenance after ischemic stroke, 5, 12 suggesting that netrin-1 play an important role in the functional recovery after ischemic stroke.
Some small-sample studies reported that serum netrin-1 levels were lower in patients with subclinical atherosclerosis, 13 type 2 diabetes mellitus 14 and multiple sclerosis than those in controls. 15 These studies revealed that elevated serum netrin-1 might decrease the risk of these diseases through reducing monocyte/macrophage accumulation, inflammation, and subsequent plaque formation. Given that these 3 diseases were closely associated with ischemic stroke, there might be a potential association between serum netrin-1 and prognosis of ischemic stroke. To date, the association between serum netrin-1 and prognosis of ischemic stroke still lacks population-based evidence. Therefore, we prospectively investigated the association between serum netrin-1 level in acute phase and prognosis within 3 months after ischemic stroke in a large cohort of patients based on CATIS (China Antihypertensive Trial in Acute Ischemic Stroke).
Methods Study Design, Study Population, and Ethics Statement
The data that support the findings of this study are available from the corresponding author on reasonable request. We established a prospective cohort study for 3-month prognostic evaluation among ischemic stroke patients from CATIS, a multicenter randomized clinical trial conducted in 26 hospitals across China from August 2009 to August 2013. The details of CATIS design and results have been described previously. 16 In brief, CATIS recruited 4071 ischemic stroke patients aged over 22 years within 48 hours of onset, and with an elevated systolic blood pressure (BP) between 140 mm Hg and <220 mm Hg. Diagnosis of ischemic stroke was confirmed by either computed tomography or magnetic resonance imaging of the brain. Patients who had a systolic BP ≥220 or diastolic BP ≥120 mm Hg, severe heart failure, acute myocardial infarction, unstable angina, atrial fibrillation, aortic dissection, cerebrovascular stenosis, resistant hypertension or deep coma at baseline, and those treated with intravenous thrombolytic therapy were excluded. For present study, 725 patients were further excluded because they did not offer blood samples, or collected blood samples were hemolyzed in storage or transport. Finally, a total of 3346 ischemic stroke patients were included in the present study ( Figure I in the online-only Data Supplement). Most baseline characteristics were balanced between patients assayed for serum netrin-1 and those not assayed (Table I in the online-only Data Supplement).
The CATIS trial is registered at clinicaltrials.gov. Present study is an exploratory study, and the measure of the serum netrin-1 is not included in the CATIS trial registration. Written informed consents were obtained from all study participants or their immediate family members. This study was approved by the Institutional Review Boards at Soochow University in China, Tulane University in the United States, and ethical committees of all participating hospitals.
Data Collection
We collected demographic characteristic, clinical features, and medical history of all patients at enrollment. Stroke severity was assessed by trained neurologists using National Institutes of Health Stroke Scale at baseline. Ischemic stroke subtype was classified as largeartery atherosclerosis (Thrombotic), cardiac embolism (Embolic), and small-vessel occlusion (Lacunar) according to the symptoms and imaging data of the patients. 17 Three BP measurements were obtained at baseline (before receiving any antihypertensive medication) when the patient was in the supine position using a standard protocol adapted from procedures recommended by the American Heart Association. 18 Routine laboratory determinations (fasting plasma glucose, blood lipids, etc) were performed for all enrolled patients in each participating hospital at admission. Dyslipidemia was defined as the abnormity of lipids in the blood (total cholesterol higher than 6.22 mmol/L or triglyceride higher than 2.26 mmol/L or low-density lipoprotein cholesterol higher than 4.14 mmol/L or high-density lipoprotein cholesterol <1.04 mmol/L) or self-reported history of physician-diagnosed dyslipidemia according to Chinese guidelines on the prevention and treatment of dyslipidemia.
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Serum Netrin-1 Detection
We collected blood samples after 8 hours of fasting within 24 hours of hospital admission. All serum samples were separated and frozen at −80°C until laboratory testing. We measured serum netrin-1 concentrations centrally at Soochow University with a quantitative sandwich ELISA detection kit from Cusabio (CSB-E11899h). Intraassay and inter-assay coefficients of variation were <8.0% and 10.0%, respectively. Laboratory technicians who measured serum netrin-1 were blinded to baseline characteristics and clinical outcomes of the study participants.
Outcome Assessment in the Prospective Cohort
The primary study outcome was a combination of death and major disability (modified Rankin Scale [mRS] score of 3-6) at the 3-month follow-up after stroke onset. Major disability (mRS score of 3-5) and stroke recurrence were the secondary outcome of this study. In addition, we also included an ordered 7-level categorical score of the mRS as a secondary outcome for neurological functional status based on a recommendation for acute stroke trials. 20 All death certificates were obtained for deceased participants, and hospital data were abstracted for stroke recurrence. A trial-wide outcomes assessment committee, blinded to treatment assignment, reviewed and adjudicated subsequent outcomes based on the criteria established in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Statistical Analysis
To analyze the association of serum netrin-1 with prognosis, the participants were divided into 4 groups according to quartiles of serum netrin-1 at admission (<315.5, 315.5-474.3, 474.4-695.4, and ≥695.5 pg/mL). Tests for linear trend of baseline characteristics across netrin-1 quartiles were performed using covariance analysis for continuous variables and Cochran-Armitage trend test for categorical variables. Multivariate logistic regression analyses were performed to assess the association between netrin-1 levels and clinical outcomes. Adjusted odds ratios (ORs) and 95% CIs of clinical outcomes were estimated for higher quartiles compared with the lowest quartile and for 1-SD increment of log-transformed netrin-1. Multivariable ordinal logistic regression was used to estimate the association of serum netrin-1 with an increase by 1 in mRS score. The covariates included in the multivariable model were age, sex, time from onset to hospitalization, antihypertensive treatment after admission to hospital, current smoking, alcohol consumption, body mass index, white blood cell count, creatinine, platelet count, dyslipidemia, blood glucose, systolic BP, and National Institutes of Health Stroke Scale score at baseline, family history of stroke, ischemic stroke subtypes, history of hypertension, diabetes mellitus, and coronary heart disease. Additionally, spline regression models were used to describe the shape of association between netrin-1 and clinical outcomes, fitting a restricted cubic spline function with four knots (at the 5th, 35th, 65th, and 95th percentiles).
Net reclassification improvement and integrated discrimination improvement were 2 statistical indexes to assess improvement in model performance accomplished by adding new markers. 21 We constructed a conventional model (only including risk factors in model 2) and a new model (including the risk factors in model 2 and serum netrin-1) by logistic regression. To assess the improvement in risk prediction for prognosis of ischemic stroke by adding serum netrin-1 to the risk factors in model 2, we calculated net reclassification improvement and integrated discrimination improvement through comparing these 2 models. We further conducted subgroup analyses and assessed the potential modified effect of 12 interesting factors on the association between serum netrin-1 and prognosis of ischemic stroke. Interactions between netrin-1 and subgroup variables on the primary outcome were tested by the likelihood ratio test with adjustment for the aforementioned covariates unless the variable was used as a subgroup variable. Two-tailed P<0.05 (except subgroup analyses) was considered to be statistically significant. In subgroup analyses, the threshold for statistical significance after Bonferroni correction for multiple comparisons was set at P<0.004. All statistical analyses were conducted using SAS (version 9.4; Cary, NC).
Results
Baseline Characteristics
The present prospective study included a total of 3346 participants (mean age 62.3 years, 63.8 % male). The median netrin-1 concentration was 474.4 pg/mL (interquartile range, 315.5-695.5 pg/mL). A review of baseline characteristics showed that age, cigarette smoking, alcohol drinking, dyslipidemia, white blood cell count, creatinine, platelet count, family history of stroke, and lacunar stroke differed by netrin-1 quartile (Table 1) .
Serum Netrin-1 Levels and Clinical Outcomes of Ischemic Stroke
After 3-month follow-up, a total of 845 participants (25.25%) experienced primary outcome (747 major disabilities and 98 deaths; Table 2 ). The cumulative rates of primary outcome at 3 months after stroke across 4 quartiles of serum netrin-1 (from low to high quartile) were 28.35%, 26.88%, 23.80%, and 21.98%, respectively (P=0.011). The OR (95% CI) of primary outcome for the highest versus lowest quartile of netrin-1 was 0.68 (0.51-0.89) after adjusting for covariates in model 1. After adjusting baseline National Institutes of Health Stroke Scale score and other factors in model 1 (model 2), the OR (95% CI) of primary outcome for the highest versus lowest quartile of netrin-1 was 0.65 (95% CI, 0.47-0.88). Moreover, each SD increase of log-transformed netrin-1 was associated with 17% (95% CI, 7%-26%) decreased risk of primary outcome for model 2.
In model 2, the adjusted OR associated with highest quartile of serum netrin-1 was 0.60 (95% CI, 0.44-0.82; P trend <0.001) for major disability (excluding deaths). Multivariable ordinal logistic regression analyses showed a better shift in the distribution of mRS score with higher netrin-1 quartiles in ischemic stroke patients (OR, 0.81; 95% CI, 0.66-0.99; Table 2 ; for both models). Multivariable-adjusted spline regression models showed a negative linear dose-response association between serum netrin-1 and primary outcome (P for linearity =0.003, P for nonlinearity =0.218; Figure 1 ). There was no association between serum netrin-1 at baseline and stroke recurrence within 3 months after stroke onset (Table I and II in the online-only Data Supplement).
Incremental Predictive Value of Serum Netrin-1 for the Prognosis of Ischemic Stroke
We examined whether adding serum netrin-1 to conventional model (all risk factors in model 2) could improve the predictive power for the prognosis of ischemic stroke. As shown in Table 3 , adding serum netrin-1 to a logistic regression model consisting of risk factors in model 2 significantly improved risk prediction for primary outcome. Adding netrin-1 quartile to the model improved net reclassification improvement of 14.74% (P=0.002) and integrated discrimination improvement of 0.40% (P=0.005) for the primary outcome. When log-transformed netrin-1 was added as a continuous variable to the model, the net reclassification improvement and integrated discrimination improvement for primary outcome were 17.08% (P<0.001) and 0.44% (P=0.004), respectively.
Subgroup Analyses
In subgroup analyses stratified by age, sex, baseline systolic BP, body mass index, baseline National Institutes of Health Stroke Scale score, time from onset to hospitalization, cigarette smoking, alcohol drinking, history of hypertension, antihypertensive treatment after admission to hospital, ischemic stroke subtypes, and dyslipidemia, the modest negative associations between serum netrin-1 and the risk of primary outcome were observed in almost all subgroups and reached statistically significance in several subgroups. Moreover, no significant interaction between serum netrin-1 levels and these interesting factors on the primary outcome was observed (all P value for interaction >0.39; Figure 2 ).
Discussion
In the present study, we investigated the association between serum netrin-1 levels at acute phase and prognosis of ischemic stroke under the indication of findings from basic medicine research. We found that increased serum netrin-1 levels at baseline were independently associated with decreased risk of the composite outcome of death or major disability at 3 months after ischemic stroke, and there was a negative linear dose-response relationship between them. Furthermore, adding serum netrin-1 to conventional risk factors (the risk factors in model 2) could improve risk prediction for the composite outcome of death or major disability. These findings suggested that increased serum netrin-1 was associated with improved prognosis of ischemic stroke and serum netrin-1 might be a potential prognostic biomarker for ischemic stroke. Further studies from various populations are needed to replicate our findings.
There have been a few population-based reports for the association between serum netrin-1 levels and cardiovascular disease. Previous case-control studies found that netrin-1 levels were decreased in patients with subclinical atherosclerosis 13 or diabetes mellitus 14 compared with healthy controls, and the anti-inflammation properties of netrin-1 might account for these associations. Consistently, data from animal studies revealed that upregulation of netrin-1 could reduce monocyte accumulation in artery, suggesting that low netrin-1 may be involved in the process of plaque formation and arterial calcification. 22, 23 It was also reported that netrin-1 had protective effects on the β-cells, and it could inhibit the progression of diabetes mellitus through increasing pancreatic islet cell mass and density. 24 In addition, patients with multiple sclerosis were found to have lower serum netrin-1 levels than healthy
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April 2019 controls, which was considered to be due to the protective properties of netrin-1 for blood vessel and blood-brain barrier. 15 Although these studies [13] [14] [15] were of small samples and not prospective, they seemed to suggest that elevated serum netrin-1 level may be a protective factor for atherosclerosis, diabetes mellitus, and multiple sclerosis.
Beyond that, human netrin-1 gene delivery could reduce macrophage accumulation, inflammation, and subsequent plaque formation, 22 and netrin-1 also potently protected the heart from ischemia-reperfusion injury. 25 These above evidence collectively indicated that circulating netrin-1 might be a protective factor in cardiovascular diseases. In terms of stroke, experimental studies have showed that netrin-1 has a role of neural and vascular protection. 10, 12 Recently, angiogenesis and neuronal migration were reported to regulate blood-brain barrier maintenance through laminin family, 26 which might account for the possible protective effect of netrin-1 against injury of blood vessel and nerve. In addition, Yu et al 12 found that netrin-1 infusion could improve neurological function and attenuated secondary impairment of blood-brain barrier. Sun et al. 10 reported that netrin-1 overexpression increased peri-infarct blood vessel density and improved motor function recovery after experimental stroke however, whether serum netrin-1 was associated with the prognosis of ischemic stroke remained unclear, and there was no related population-based evidence so far.
We conducted a large prospective multicenter study to investigate the possible relationship between serum netrin-1 and prognosis of ischemic stroke among patients from CATIS trail. Standardized protocols and strict quality control procedures were used in baseline data collection and outcome assessment during follow-up. Furthermore, comprehensive information about potential confounders was collected and controlled in the multivariate models. After controlling these potential confounders, we found that increased serum netrin-1 was significantly associated with decreased risk of the composite outcome of death or major disability at 3 months after stroke onset. The patients in the highest quartile of netrin-1 showed a 35% decreased risk of death or disability compared with those in the lowest quartile, and each SD increase of log-transformed netrin-1 led to17% decreased risk of death or disability. Furthermore, the addition of serum netrin-1 to conventional risk factors was shown to improve risk prediction for the composite outcome of death or major disability, suggesting that serum netrin-1 at baseline may be a potential predictive biomarker for prognosis of ischemic stroke. Our study provided further evidence about the potential role of serum netrin-1 on prognosis of ischemic stroke, and had important clinical implications for early prevention and intervention. With regard to these findings, we hypothesized that serum netrin-1 might be useful in risk stratification of ischemic stroke prognosis and could assist the selection of high-risk patients in future clinical practice. If patients have low serum netrin-1 levels at admission, they may be at high risk of poor prognosis and should receive aggressive monitoring and therapeutic interventions. Further studies are warranted to replicate our findings. Several biological mechanisms could explain the observed effect of serum netrin-1 on prognosis of ischemic stroke. Experiments studies have shown that netrin-1 have anti-inflammatory properties 5, 6 and antiapoptosis effects on endothelial cell 8 and neuron. 7 Netrin-1 rescues neuron loss by attenuating secondary apoptosis in rats with focal cerebral infarction. 9 Ex-vivo netrin-1 overexpression could promote migration of neuron to cerebral infarction region and reduce Model 1, adjusting for age, sex, time from onset to hospitalization, antihypertensive treatment after admission to hospital, current smoking, alcohol consumption, body mass index, white blood cell count, creatinine, platelet count, dyslipidemia, blood glucose and systolic BP at baseline, family history of stroke, ischemic stroke subtypes, history of hypertension, diabetes mellitus, and coronary heart disease. Model 2, further adjusting for baseline National Institutes of Health Stroke Scale score based on adjusting for factors in model 1.
*Odds ratio and 95% CI of increase by 1 in modified Rankin Scale score. Adjusted odds ratios (ORs) of primary outcome (death or major disability) according to serum netrin-1. OR and 95% CI derived from restricted cubic spline regression, with knots placed at the 5th, 35th, 65th, and 95th percentiles of netrin-1. OR adjusted for the same variables as model 2 in Table 2 .
April 2019 infarct volume. 11 Some studies also found that netrin-1 ameliorated blood-brain barrier impairment secondary to ischemic stroke by up-regulating the levels of tight junction proteins and diminishing extravasation of albumin. 12 In addition, netrin-1 overexpression can improve neurobehavioral outcomes after ischemic brain injury through inhibition of the Notch1 signaling pathway. 27 Our study has several limitations that need to be interpreted. First, this study was an observational study based on CATIS trial, thus a selection bias might exist. Given that CATIS excluded the patients with BP ≥220/120 mm Hg or other serious conditions at admission, the results of present study may not be generalizable to all ischemic stroke patients. However, the proportion of patients with BP ≥220/120 mm Hg Table 2 , including age, sex, time from onset to hospitalization, antihypertensive treatment after admission to hospital, current smoking, alcohol consumption, body mass index, white blood cell count, creatinine, platelet count, dyslipidemia, blood glucose, and systolic BP at baseline, family history of stroke, ischemic stroke subtypes, history of hypertension, diabetes mellitus, and coronary heart disease and National Institutes of Health Stroke Scale score at baseline. IDI indicates integrated discrimination index; and NRI, net reclassification improvement. Table 2 unless the variable was used as a subgroup variable. Odds ratio and 95% CIs were showed by forest plot. NIHSS indicates National Institutes of Health Stroke Scale; and OR, odds ratio.
is low in China, and baseline characteristics of patients in this study were similar to those from the China National Stroke Registry. 28 In addition, compared with US and Europe, the severity of ischemic stroke and the proportion of cardio-embolic stroke in China are relatively low. Therefore, further studies conducted among participants with different social and cultural backgrounds are needed to replicate our findings. Second, serum netrin-1 concentrations were tested only once at baseline, so we were unable to examine the association of netrin-1 changes with prognosis. However, previous studies reported that serum netrin-1 levels in individuals were relatively stable over 60 days. 15 Finally, relatively few number of stroke recurrence were observed during 3-month follow-up of relatively short time, which might limit our power to detect significant association between serum netrin-1 and stroke recurrence. Further long-term follow-up studies are required to verify their relationships.
Conclusions
We found that increased serum netrin-1 was associated with improved prognosis at 3 months after ischemic stroke. Adding netrin-1 to conventional risk factors significantly improved risk prediction for death or major disability in patients with ischemic stroke, indicating that serum netrin-1 may be a potential prognostic marker for ischemic stroke. Further studies are needed to validate our findings and determine whether netrin-1 measurements have any utility in clinical settings.
